You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR DINOPROSTONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DINOPROSTONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00140114 ↗ Sublingual Versus Vaginal Misoprostol for Labor Induction at Term Completed American University of Beirut Medical Center Phase 3 2004-01-01 Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. In contradistinction to prostaglandin E2 preparations (dinoprostone, Prepidil, Cervidil), misoprostol is inexpensive and available in scored tablets that can be broken and inserted vaginally. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance as both a labor induction and a cervical ripening agent. Such off-label indication has been endorsed by the American College of Obstetricians and Gynecologists and other medical bodies. Recently, FDA approved a new label for the use of cytotec during pregnancy which removed pregnancy as a contraindication for its use. Vaginal administration seems to be more efficacious than when given orally, although there is the worry of uterine tachysystole and hyperstimulation with vaginal doses > 50-µg. The use of sublingual misoprostol for cervical ripening at term was recently investigated in two studies that compared it to the oral route, on the assumption that the sublingual route would have the higher efficacy of the vaginal route by avoiding the first pass effects of the gastrointestinal and hepatic systems, while having lower hyperstimulation rates by avoiding the direct effects on the cervix. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the induction of labor at term. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00148473 ↗ Oral Versus Vaginal Misoprostol for Induction of Labor Completed Bangkok Metropolitan Administration Medical College and Vajira Hospital Phase 2/Phase 3 2000-03-01 The purpose of this study is to compare the efficacy between a single dose of oral misoprostol 100 microgram and vaginal misoprostol 50 microgram for induction of labor.
NCT00299754 ↗ Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study) Completed National Healthcare Group, Singapore Phase 3 2003-01-01 Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.
NCT00299754 ↗ Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study) Completed KK Women's and Children's Hospital Phase 3 2003-01-01 Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.
NCT00308711 ↗ Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor Completed Ferring Pharmaceuticals Phase 3 2006-04-01 The purpose of this study is to determine whether the misoprostol vaginal insert (50 mcg and 100 mcg) can safely and effectively speed time to vaginal delivery compared to Cervidil (R) in women who need to have cervical ripneing and induction of labor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DINOPROSTONE

Condition Name

Condition Name for DINOPROSTONE
Intervention Trials
Cervical Ripening 15
Induction of Labor 10
Induction of Labor Affected Fetus / Newborn 6
Labor, Induced 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DINOPROSTONE
Intervention Trials
Fetal Membranes, Premature Rupture 7
Rupture 7
Infertility 2
Premature Birth 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DINOPROSTONE

Trials by Country

Trials by Country for DINOPROSTONE
Location Trials
United States 47
Egypt 19
Japan 13
Korea, Republic of 5
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DINOPROSTONE
Location Trials
Utah 3
Florida 2
Delaware 2
California 2
Arizona 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DINOPROSTONE

Clinical Trial Phase

Clinical Trial Phase for DINOPROSTONE
Clinical Trial Phase Trials
Phase 4 23
Phase 3 22
Phase 2/Phase 3 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DINOPROSTONE
Clinical Trial Phase Trials
Completed 42
Unknown status 15
Not yet recruiting 12
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DINOPROSTONE

Sponsor Name

Sponsor Name for DINOPROSTONE
Sponsor Trials
Cairo University 17
Ferring Pharmaceuticals 8
Seoul National University Hospital 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DINOPROSTONE
Sponsor Trials
Other 94
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.